<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20928">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02834442</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-E01</org_study_id>
    <nct_id>NCT02834442</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Double Blind, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-7117 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of
      MT-7117 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (masked roles unspecified)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by number of participants with adverse events</measure>
    <time_frame>up to Day56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by vital signs</measure>
    <time_frame>up to Day56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by physical examination</measure>
    <time_frame>up to Day56</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by ECG</measure>
    <time_frame>up to Day21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability as measured by laboratory safety assessments</measure>
    <time_frame>up to Day21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax)</measure>
    <time_frame>96 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent elimination half-life in plasma</measure>
    <time_frame>96 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single ascending dose, MT-7117 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose, MT-7117 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-7117</intervention_name>
    <arm_group_label>Single ascending dose, MT-7117 or Placebo</arm_group_label>
    <arm_group_label>Multiple ascending dose, MT-7117 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Single ascending dose, MT-7117 or Placebo</arm_group_label>
    <arm_group_label>Multiple ascending dose, MT-7117 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy and free from clinically significant illness or disease

          -  Male or female subjects aged 18 to 55 years or elderly male subjects aged ≥65

          -  A body weight of ≥60 kg for males and ≥50 kg for females, and a body mass index
             ranging from 18 to 30 kg/m2

        Exclusion Criteria:

          -  Participated in more than three clinical studies involving administration of an IMP
             in the previous year, or any study within 12 weeks

          -  Clinically significant endocrine, thyroid, hepatic, respiratory, gastro intestinal,
             renal, cardiovascular or skin disease, or history of any significant
             psychiatric/psychotic illness disorder

          -  Clinically relevant abnormal medical history, physical findings or laboratory values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Information Desk</last_name>
    <email>info@mt-pharma-eu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>United Kingdom</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>July 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
